H eart failure with preserved ejection fraction (HFpEF) is a diverse syndrome marked by myocyte hypertrophy, concentric left ventricular remodeling, and end-diastolic stiffness. 1 HFpEF is seen predominantly in the elderly and hypertensive and is associated with several comorbidities such as obesity, anemia, diabetes mellitus, and lung and kidney disease. [2] [3] [4] These comorbidities contribute both to the diastolic stiffness directly, as well as result in systemic inflammatory derangements that lead to cardiac morbidity and mortality. [5] [6] [7] This systemic inflammation may also cause adverse myocardial remodeling in HFpEF by disrupting coronary endothelial and microvascular function, inducing differentiation of myofibroblasts, and altering paracrine communication between cardiomyocytes. 8 (Circ Cardiovasc Imaging. 2016;9:e005905.
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Analysis of hypertensive patients with and without HFpEF has revealed elevated serum markers of collagen production and turnover in patients with higher degrees of HF symptoms. 9 Endomyocardial biopsy of patients with HFpEF demonstrated more collagen type I and collagen cross-linking, which correlated to higher degrees of diastolic dysfunction by tissue Doppler. 10, 11 Stimulation of cardiac fibroblasts in HFpEF patients with transforming growth factor-β resulted in differentiation into myofibroblasts, which increased type I collagen and reduced matrix metalloproteinase-1 increasing diastolic stiffness through collagen deposition in the extracellular membrane induced by inflammation. 12 Taken together, these data indicate that myocardial fibrosis may play a major role in the development of HFpEF, making it an attractive marker of disease progression and prognosis.
Myocardial fibrosis can be determined by examination of endomyocardial biopsy; however, its practicality in evaluation of all HFpEF patients is limited, given the exceedingly large and growing HFpEF population, 13, 14 and the invasive nature of the biopsy. Therefore, there has been significant interest in determining whether various cardiac magnetic resonance (CMR) parameters such as late gadolinium enhancement (a marker of replacement fibrosis), increased native myocardial T2 relaxation time (a marker of edema), increased native myocardial T1 relaxation time (a marker of interstitial fibrosis), and the extracellular volume fraction (ECV, a combined marker of interstitial fibrosis and inflammation) may prove to be meaningful imaging-based biomarkers for patients with HFpEF.
In this issue of Circulation: Cardiovascular Imaging, Duca et al 15 meticulously investigated the potential utility of ECV as a biomarker to be used in the evaluation and management of HFpEF. They studied 117 patients with HFpEF all of whom underwent CMR to measure ECV and several other parameters, echocardiography, invasive coronary angiography, and right heart catheterization. A subset of 18 patients also underwent a left ventricular endomyocardial biopsy to derive a histology-based reference standard for ECV. Patient outcomes, defined as cardiac death or hospitalization for heart failure, were collected during a mean follow-up period of 24 months. As an initial validation, the authors compared the CMR-measured ECV against the histology-measured gold-standard and found a modest correlation between the 2 parameters (r=0.494). Based on Bland-Altman analysis, the CMR-measured ECV had a rather considerable error of ≈25% when compared with the histology reference standard. Next the authors appropriately studied the relationships between CMR-measured ECV and several clinically important parameters associated with HFpEF. They found that ECV was poorly correlated with most of them, as reflected by low r values: E/A ratio (r=0.254), right atrial pressure (r=0.205), stroke volume (r=−0.203), N-terminal prohormone of brain natriuretic peptide (r=0.369), 6-minute walk distance (r=-0.276), and New York Heart Association Functional Class (r=0.242). The authors then examined the ability of CMR-measured ECV to risk-stratify patients with HFpEF. They found that patients with an elevated ECV fraction were more likely to have a cardiac event, mostly related to heart failure hospitalization. The prognostic ability of ECV seemed to be most predictive in the first 6 months of follow-up; after that, the prognostic value of ECV is unclear. In addition, when relevant clinical and hemodynamic parameters were included as part of a multivariate analysis, ECV was not found to be an independent predictor of patient outcomes. Interestingly, the only multivariate predictors of poor outcomes were elevated pulmonary vascular resistance, right ventricular end-diastolic volume, with a trend toward significance for eGFR and N-terminal prohormone of brain natriuretic peptide. Biomarkers for HFpEF It is not completely clear whether ECV is a better tool for risk stratifying patients with HFpEF than renal function, N-terminal prohormone of brain natriuretic peptide levels, or other CMR parameters such as the burden of late gadolinium enhancement. Nevertheless, the novelty of these data provides a highly sought-after signal that ECV may yet prove to be a clinically valuable addition to CMR imaging in this patient population. In addition, this important work verifies that extracellular fibrosis is present in HFpEF and is at least weakly associated with the pathophysiologic and symptom-based parameters common to the disease process.
A potential explanation for the lack of predictive value of ECV after multivariate regression is the heterogeneity of the HFpEF syndrome. There was a wide range of N-terminal prohormone of brain natriuretic peptide and an assortment of patient comorbidities, as seen in other HFpEF data sets. 16 It is possible that different combinations of comorbidities and hemodynamic load may result in different cardiovascular phenotypes with differing prognosis. In a similar study by the same group, symptom severity was one of the most important predictors of poor outcome in a large HFpEF cohort, which itself was related to obesity, age, elevated pulmonary pressures, and higher grades of diastolic dysfunction. 17 Obesity, for example, has been strongly associated with the development of HFpEF; however, it has multiple noncardiac effects and itself may contribute to heart failure-and non-heart failure-related morbidity and mortality. In addition, increased ECV may be an indication of fibrosis and inflammation, but not necessarily reflect the severity of ongoing metabolic and hemodynamic derangements affecting other organ systems. Autopsy analysis of 124 hearts of patients with HFpEF demonstrated an inverse relationship between microvascular density and myocardial fibrosis, indicating that coronary microvascular dysfunction and subsequent fibrosis may be one of the pathophysiologic mechanisms of HFpEF. 18 It is yet to be determined whether microvascular dysfunction in living HFpEF patients correlates with ECV, and how it relates to disease severity or as a predictor of poor outcomes. Because of the heterogeneity of the HFpEF syndrome, classification schemes have been proposed to characterize HFpEF phenotypes based on predisposition and clinical presentation, calling attention the need for better discrimination between HFpEF phenotypes to better design therapies. 19 The use of ECV as an imaging-based biomarker continues to be of great interest, but the data presented by Duca et al 15 suggest that further studies are needed before ECV can be recommended for routine use in patients with HFpEF. In addition, the complexity of HFpEF and interaction with comorbidities makes this disease entity difficult to characterize and target therapeutics. As the search for the perfect HFpEF biomarker continues, we can find solace in the fact that everyday tools such as assessment of symptom class and natriuretic peptides might help us identify those patients at risk for adverse outcomes.
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